Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
Recruiting · NCT07654179 · Interventional (participants receive a specific treatment) · Lead sponsor: Riphah International University
View the official record on ClinicalTrials.gov →Interventions studied
Antidepressant TherapyMetformin
What this trial is about
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Group I: Normal Controls Group II: Depression Group III: Obesity
- Group IV and V:
- Age ≥ 18 years
- Both males and females
- Recurrent depressive disorder (6A71) according to ICD-11,
- Asian cut off: Obese and overweight (BMI \< 23)
- BDI score ≥ 13 or PHQ score ≥ 4
- Either medication-naïve or medication-free for at least 2 weeks before enrollment, or the patient did not take antidepressants during the last 7 days before study entry (discontinuation of effective medication to enable study participation is prohibited)
- In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days before study entry (any changes in medication dose or frequency of therapy must be answered with no)
Exclusion criteria
- Groups I-III: Negative Controls (Normal: no depression and Obesity for SNP comparison only)
- Age less than 18
- Dementia/ Mentally impaired who can not fill self report performas for inclusion criteria
- Group IV: Positive Control (RCT patients)
- Patients with comorbid conditions (HTN, CKD) if taking any drug for that condition.
- The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator, or the investigator study site.
- The patient did not participate in other interventional trials during the 6 months before and at the time of this trial. The patient does not have a history of non-response to antidepressants included in the study.
- The patient has not given birth within the 6 months before study entry and is not breastfeeding
- The patient did not receive treatment with ketamine, irreversible MAO inhibitor (e.g. tranylcypromine), electroconvulsive therapy (ECT) or other stimulatory treatments in the index episode.
- The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression.
- The patient does not meet the criteria for alcohol use disorder (DSM-5: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 - F19.20) in DSM-5, and a urine/serum drug screening is negative (except for benzodiazepines and opiates).
- The patient does not have:
- A known allergy or contraindication against antidepressants included in the study
- History of suicidal tendencies
- Uncontrolled hepatic disorder, renal or cardiovascular disease
- Untreated hypothyroidism
- History of myocardial infarction or stroke
- Symptomatic peripheral arterial disease
- Monogenic familial hypercholesterolemia
Where it is running
4 locations listed.
- Pakistan Railway Hospital - Rawalpindi, Punjab Province, Pakistan
- Afifa Siddique - Rawalpindi, Punjab Province, Pakistan
- Pakistan Railway Hospital - Rawalpindi, Punjab Province, Pakistan
- Afifa Siddique - Rawalpindi, Punjab Province, Pakistan